RxDoctor Payments DataLook up a doctor →

Sudarshan Sharma, MD

Gynecologic Oncology · Hinsdale, ILNPI 1740265974

Payments from drug & device makers

$2,589,142in general payments, 2019–2025

Across 271 payments — averaging $9554.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.5M
  • GSK$665K
  • Genentech, Inc.$202K
  • AstraZeneca$149K
  • Clovis Oncology, Inc.$103K
  • Pharmaand GmbH$5K
  • plus $1K from 15 others
$4,257in research payments, 2019–2025

Across 3 payments — averaging $1419.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Karyopharm Therapeutics Inc.$3K
  • F. Hoffmann-la Roche AG$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,589,142 in reported general payments places this provider in the 95th percentile of 64 gynecologic oncology providers in Illinois.

See all gynecologic oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$935,951
Medicare patients
235
Services billed
36,611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Hinsdale

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →